Polen Capital Management LLC Sells 1,256 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Polen Capital Management LLC lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.8% in the fourth quarter, HoldingsChannel reports. The fund owned 4,248 shares of the medical research company’s stock after selling 1,256 shares during the period. Polen Capital Management LLC’s holdings in Charles River Laboratories International were worth $784,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CRL. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after buying an additional 47,221 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Charles River Laboratories International by 7.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company’s stock valued at $102,079,000 after acquiring an additional 37,753 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 2.3 %

NYSE:CRL opened at $175.02 on Tuesday. The company has a market cap of $8.95 billion, a PE ratio of 1,166.77, a PEG ratio of 4.54 and a beta of 1.45. The stock has a 50-day simple moving average of $167.46 and a 200 day simple moving average of $184.33. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $274.77.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm’s revenue was down 1.1% compared to the same quarter last year. During the same period last year, the company earned $2.46 earnings per share. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Robert W. Baird cut their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. Bank of America decreased their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. The Goldman Sachs Group reduced their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Finally, Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $198.36.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).